IL127564A0 - Solid oral dosage forms of valsartan - Google Patents

Solid oral dosage forms of valsartan

Info

Publication number: IL127564A0
Authority: IL; Israel
Prior art keywords: valsartan; dosage forms; oral dosage; solid oral; solid
Prior art date: 1996-06-27

Application number

IL12756497A

Other languages

English (en)

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-06-27

Filing date

1997-06-18

Publication date

1999-10-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10795969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL127564(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-06-18 Application filed by Novartis Ag filed Critical Novartis Ag

1999-10-28 Publication of IL127564A0 publication Critical patent/IL127564A0/xx

Links

239000004072 C09CA03 - Valsartan Substances 0.000 title 1
239000006186 oral dosage form Substances 0.000 title 1
239000007787 solid Substances 0.000 title 1
SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title 1
229960004699 valsartan Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Orthopedic Medicine & Surgery (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IL12756497A 1996-06-27 1997-06-18 Solid oral dosage forms of valsartan IL127564A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9613470.5A GB9613470D0 (en)	1996-06-27	1996-06-27	Small solid oral dosage form
PCT/EP1997/003172 WO1997049394A2 (en)	1996-06-27	1997-06-18	Sold oral dosage forms of valsartan

Publications (1)

Publication Number	Publication Date
IL127564A0 true IL127564A0 (en)	1999-10-28

Family

ID=10795969

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL12756497A IL127564A0 (en)	1996-06-27	1997-06-18	Solid oral dosage forms of valsartan
IL195339A IL195339A0 (en)	1996-06-27	2008-11-17	Solid oral dosage forms of valsartan

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL195339A IL195339A0 (en)	1996-06-27	2008-11-17	Solid oral dosage forms of valsartan

Country Status (32)

Country	Link
US (3)	US6294197B1 (de)
EP (7)	EP1767206B1 (de)
JP (5)	JP2000506540A (de)
KR (6)	KR20060079260A (de)
CN (3)	CN1133427C (de)
AR (2)	AR008618A1 (de)
AT (3)	ATE371449T1 (de)
BR (1)	BR9709956A (de)
CA (2)	CA2673462C (de)
CO (1)	CO4870755A1 (de)
CY (1)	CY2553B1 (de)
CZ (1)	CZ296850B6 (de)
DE (3)	DE69738089T2 (de)
DK (3)	DK1767206T3 (de)
ES (3)	ES2335683T3 (de)
GB (1)	GB9613470D0 (de)
HU (1)	HU229134B1 (de)
ID (1)	ID17553A (de)
IL (2)	IL127564A0 (de)
MY (3)	MY123149A (de)
NO (2)	NO317181B1 (de)
NZ (2)	NZ333385A (de)
PE (1)	PE87498A1 (de)
PL (2)	PL188233B1 (de)
PT (3)	PT1410797E (de)
RU (5)	RU2294743C2 (de)
SI (2)	SI1410797T1 (de)
SK (1)	SK285902B6 (de)
TR (1)	TR199802698T2 (de)
TW (1)	TW473394B (de)
WO (1)	WO1997049394A2 (de)
ZA (1)	ZA975673B (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9613470D0 (en)	1996-06-27	1996-08-28	Ciba Geigy Ag	Small solid oral dosage form
US20030045561A1 (en) *	2001-02-06	2003-03-06	Smithkline Beecham Corporation	Method of treating isolated systolic hypertension
ES2214013T3 (es) *	1998-03-04	2004-09-01	Takeda Chemical Industries Ltd	Preparacion de liberacion sostenida para un antagonista de aii, su produccion y su uso.
KR100554924B1 (ko)	1998-05-18	2006-03-03	다케다 야쿠힌 고교 가부시키가이샤	구강내 붕괴 정제
ES2289814T3 (es) *	1998-07-10	2008-02-01	Novartis Pharma Ag	Combinacion antihipertensiva de valsartan y bloqueador de canales del calcio.
KR100646716B1 (ko)	1998-12-23	2006-11-17	노파르티스 아게	Ａｔ-1 또는 ａｔ-2 수용체의 증가와 관련된 질환의치료에 있어서 ａｔ-1 수용체 길항제 또는 ａｔ-2 수용체조절제의 용도
EP1714651A1 (de) *	1999-01-26	2006-10-25	Novartis AG	Verwendung von Angiotensin II Rezeptorantagonisten zur Behandlung von akutem myokardischen Infarkt
CN101011390A (zh)	1999-01-26	2007-08-08	诺瓦提斯公司	血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
EP1872797A3 (de) *	1999-08-24	2008-04-02	Medicure International Inc.	Behandlung kardiovaskulärer und verwandter Leiden
DE10066408B4 (de) *	2000-03-24	2010-03-18	3M Espe Dental Ag	Verwendung feinkörniger Pulver für supragingivales Pulverstrahlen
CA2311734C (en) *	2000-04-12	2011-03-08	Bristol-Myers Squibb Company	Flash-melt oral dosage formulation
US20020132839A1 (en) *	2000-06-22	2002-09-19	Ganter Sabina Maria	Tablet formulations comprising valsartan
CZ20024180A3 (cs) *	2000-06-22	2003-04-16	Novartis Ag	Pevné orální farmaceutické kompozice obsahující valsartan
AU2005200815B2 (en) *	2000-06-22	2008-01-17	Novartis Ag	Solid valsartan pharmaceutical compositions
BR0112665A (pt)	2000-07-19	2003-06-24	Novartis Ag	Sais
PE20020617A1 (es) *	2000-08-22	2002-08-05	Novartis Ag	Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
US20060089389A1 (en)	2000-08-22	2006-04-27	Malcolm Allison	Combination
US8168616B1 (en)	2000-11-17	2012-05-01	Novartis Ag	Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
US20040219208A1 (en) *	2001-08-03	2004-11-04	Ryu Kawamura	Sustained-release medicines
GB0209265D0 (en) *	2002-04-23	2002-06-05	Novartis Ag	Organic compounds
EG24716A (en) *	2002-05-17	2010-06-07	Novartis Ag	Combination of organic compounds
DE10230272A1 (de) *	2002-07-05	2004-01-22	Solvay Pharmaceuticals Gmbh	AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
EP1382334A1 (de) *	2002-07-11	2004-01-21	Université de Picardie Jules Verne	Verwendung von Angiotensin II AT1-Rezeptorblockern, allein oder in Kombination mit Thiazide oder Angiotensin II zur Behandlung von Schlaganfall
EP1950204A1 (de)	2003-03-17	2008-07-30	Teva Pharmaceutical Industries Ltd.	Amorphe Form von Valsartan
US7199144B2 (en) *	2003-04-21	2007-04-03	Teva Pharmaceuticals Industries, Ltd.	Process for the preparation of valsartan and intermediates thereof
EP1511739B1 (de) *	2003-03-17	2008-04-30	Teva Pharmaceutical Industries Ltd.	Polymorphe formen von valsartan
EP1556363A2 (de) *	2003-04-21	2005-07-27	Teva Pharmaceutical Industries Limited	Verfahren zur herstellung von valsartan und zwischenprodukte davon
US7378531B2 (en) *	2003-04-21	2008-05-27	Teva Pharmaceutical Industries Ltd	Process for the preparation of valsartan
KR100882156B1 (ko)	2003-08-08	2009-02-06	아지노모토 가부시키가이샤	나테글리니드 함유 제제
GB0325605D0 (en) *	2003-11-03	2003-12-10	Novartis Ag	Combination of organic compounds
EP1680095A2 (de) *	2003-11-03	2006-07-19	Zentiva, a.s.	Valsartan enthaltende formulierung
JP2005187793A (ja) *	2003-12-24	2005-07-14	Rohm & Haas Electronic Materials Llc	改良された接着剤
WO2005082329A2 (en) *	2004-02-19	2005-09-09	Ranbaxy Laboratories Limited	Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide
WO2005089720A1 (en) *	2004-03-10	2005-09-29	Ranbaxy Laboratories Limited	Valsartan tablets and the process for the preparation thereof
CN1993355A (zh)	2004-09-02	2007-07-04	特瓦制药工业有限公司	奥美沙坦酯的纯化方法
SI2801354T1 (sl) *	2004-10-08	2017-07-31	Forward Pharma A/S	Farmacevtske sestave z nadzorovanim sproščanjem, ki zajemajo ester fumarne kisline
JP4705108B2 (ja) *	2004-10-15	2011-06-22	ズートツッカーアクチェンゲゼルシャフトマンハイム／オクセンフルト	改良されたパンコーティング法
EA015108B1 (ru) *	2004-12-24	2011-06-30	КРКА, д.д., НОВО МЕСТО	Способ получения твердой фармацевтической композиции, содержащей валсартан
EP1674080A1 (de) *	2004-12-24	2006-06-28	KRKA, D.D., Novo Mesto	Feste pharmazeutische Zusammensetzung valsartan enthaltend
FR2882260A1 (fr) *	2005-02-21	2006-08-25	Flamel Technologies Sa	Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
KR101310037B1 (ko) *	2005-05-31	2013-09-24	밀란 인크.	네비볼롤을 함유하는 조성물
EP1812411A2 (de) *	2005-07-05	2007-08-01	Teva Pharmaceutical Industries Ltd.	Verfahren zur herstellung von valsartan
GB0513888D0 (en) *	2005-07-06	2005-08-10	Btg Int Ltd	Core 2 GLCNAC-T Inhibitors II
WO2007052307A2 (en) *	2005-10-31	2007-05-10	Lupin Limited	Stable solid oral dosage forms of valsartan
RU2309732C1 (ru) *	2006-03-13	2007-11-10	Олег Ильич Эпштейн	Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
US20100029654A1 (en) *	2006-03-23	2010-02-04	Mount Sinai School Of Medicine	Cardiovascular compositions and use of the same for the treatment of alzheimer's disease
EA200802440A1 (ru)	2006-06-06	2009-06-30	Олег Ильич ЭПШТЕЙН	Лекарственное средство для лечения ожирения, сахарного диабета и заболеваний с нарушением толерантности к глюкозе
EP2043607A2 (de) *	2006-06-23	2009-04-08	Usv Limited	Verfahren zur herstellung von mikronisiertem valsartan
GB0612540D0 (en)	2006-06-23	2006-08-02	Novartis Ag	Galenical formulations of organic compounds
EP1897537A1 (de) *	2006-09-04	2008-03-12	Novartis AG	Zusammensetzung enthaltend einen Angiotensin II antagonisten
PE20081364A1 (es) *	2006-09-04	2008-12-04	Novartis Ag	Composicion farmaceutica que comprende valsartan
CN101534798B (zh) *	2006-10-30	2012-02-15	韩诺生物制约株式会社	包含噻嗪类和血管紧张素ⅱ受体阻断剂的控释药物组合物
WO2008064338A2 (en) *	2006-11-22	2008-05-29	Rubicon Research Pvt. Ltd.	Valsartan formulation for pulsatile delivery
US20110027358A1 (en) *	2007-03-29	2011-02-03	Rajesh Kshirsagar	Valsartan tablet formulations
TR200703568A1 (tr)	2007-05-24	2008-07-21	Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket�	Valsartan formülasyonları
JP5623275B2 (ja) *	2007-07-31	2014-11-12	カーギルインコーポレイテッド	直接打錠可能なデキストロース
GB0715628D0 (en) *	2007-08-10	2007-09-19	Generics Uk Ltd	Solid valsartan composition
CN101396366B (zh) *	2007-09-25	2010-10-13	浙江华海药业股份有限公司	含缬沙坦的固体口服制剂及其制备方法
WO2009045795A2 (en) *	2007-09-28	2009-04-09	Novartis Ag	Galenical formulations of aliskiren and valsartan
MX2010003923A (es)	2007-10-09	2010-05-05	Novartis Ag	Formulacion farmaceutica de valsartan.
CN101848700A (zh)	2007-11-06	2010-09-29	诺瓦提斯公司	基于血管紧张素受体拮抗剂/阻断剂(arb)和中性内肽酶(nep)抑制剂的超结构的双重作用的药物组合物
EP2067470A1 (de) *	2007-12-03	2009-06-10	Laboratorios Lesvi, S.L.	Pharmazeutische Zusammensetzungen mit Valsartan und Herstellungsverfahren dafür
WO2009084003A1 (en) *	2007-12-31	2009-07-09	Lupin Limited	Pharmaceutical compositions of amlodipine and valsartan
JP2011513328A (ja) *	2008-02-28	2011-04-28	ノバルティスアーゲー	バルサルタン固体経口投薬形態及びそのような製剤を製造する方法
US20090226516A1 (en) *	2008-03-04	2009-09-10	Pharma Pass Ii Llc	Sartan compositions
US20090226515A1 (en) *	2008-03-04	2009-09-10	Pharma Pass Ii Llc	Statin compositions
US20110117194A1 (en) *	2008-04-29	2011-05-19	Hanall Biopharma Co., Ltd.	Pharmaceutical formulation containing angiotensin-ii receptor blocker
WO2009149493A1 (en) *	2008-06-09	2009-12-17	Dimerix Bioscience Pty Ltd	Novel receptor hetero-dimers/-oligomers
KR101033975B1 (ko) *	2008-10-10	2011-05-11	이희엽	직접압축법을 이용한 발사르탄 함유 고형 경구 제형의 제조방법 및 이에 따라 제조된 고형 경구 제형
DE102008051783A1 (de)	2008-10-17	2010-04-22	Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg	Valsartan enthaltende Tablette
WO2010075347A2 (en)	2008-12-23	2010-07-01	Takeda Pharmaceutical Company Limited	Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
EP2405899A2 (de)	2009-03-11	2012-01-18	Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi	Valsartan-formulierungen
RU2398570C1 (ru) *	2009-04-17	2010-09-10	Илья Николаевич Медведев	Способ снижения содержания микровезикул в крови при стабильной стенокардии напряжения i-ii функционального класса с артериальной гипертонией
KR101084783B1 (ko) *	2009-09-01	2011-11-22	삼성에스디아이 주식회사	이차 전지 및 그의 제조 방법
WO2011027021A1 (en) *	2009-09-01	2011-03-10	Orion Corporation	A method for the treatment of hypertension
ES2364011B1 (es)	2009-11-20	2013-01-24	Gp Pharm, S.A.	Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
CN101897675B (zh) *	2010-02-10	2012-11-21	温士顿医药股份有限公司	含有凡尔沙坦或其药学上可接受的盐的固体剂型口服医药组成物
WO2011102702A2 (en)	2010-02-16	2011-08-25	Krka, D. D., Novo Mesto	Process for the preparation of oral solid dosage forms comprising valsartan
AR083417A1 (es)	2010-10-14	2013-02-21	Novartis Ag	Composiciones farmaceuticas que contienen un dgat1 inhibidor
JP5882796B2 (ja)	2011-03-31	2016-03-09	キヤノン株式会社	振動体の駆動方法、振動装置、該振動装置を有する駆動装置、及び光学機器
GB201116993D0 (en) *	2011-10-03	2011-11-16	Ems Sa	Pharmaceutical compositions of antihypertensives
WO2013098268A2 (en)	2011-12-26	2013-07-04	Novartis Ag	Tablets and dry-coated agents
WO2013098576A1 (en)	2011-12-31	2013-07-04	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Immediate release pharmaceutical composition of valsartan
WO2013098578A1 (en)	2011-12-31	2013-07-04	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
JP6018420B2 (ja) *	2012-06-05	2016-11-02	ニプロ株式会社	アンジオテンシンｉｉ受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物
KR101944085B1 (ko) *	2012-09-06	2019-01-30	한국콜마주식회사	발사르탄 함유 고형 경구제형 및 그 제조방법
JP2014062064A (ja) *	2012-09-21	2014-04-10	Ohara Yakuhin Kogyo Kk	バルサルタン含有錠剤の製造方法
JP6238831B2 (ja) *	2014-04-25	2017-11-29	沢井製薬株式会社	バルサルタン含有錠剤及びその製造方法
JP6141472B2 (ja) *	2016-03-02	2017-06-07	大原薬品工業株式会社	バルサルタン含有錠剤の製造方法
WO2018002673A1 (en)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Novel formulations of angiotensin ii receptor antagonists
WO2019241590A1 (en)	2018-06-14	2019-12-19	Astrazeneca Uk Limited	Methods for treatment of hypertension with an angiotensin ii receptor blocker pharmaceutical composition
EP4295839A1 (de)	2022-06-20	2023-12-27	KRKA, d.d., Novo mesto	Kombination aus valsartan und indapamid

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3200039A (en)	1962-05-28	1965-08-10	Pfizer & Co C	Non-granulated tablets with 20% sorbitol in a particle size of from about 100mu to about 2000mu
GB1422176A (en)	1973-05-05	1976-01-21	Beecham Group Ltd	Pharmaceutical tablets
AU528098B2 (en)	1978-11-16	1983-04-14	Beecham Group Plc	Analgesic tablet
US4353887A (en)	1979-08-16	1982-10-12	Ciba-Geigy Corporation	Divisible tablet having controlled and delayed release of the active substance
US4238485A (en) *	1979-10-29	1980-12-09	Merck & Co., Inc.	Novel pharmaceutical compositions
EP0070127A3 (de)	1981-07-10	1983-08-17	Beecham Group Plc	Tabletten
US4543359A (en) *	1982-10-01	1985-09-24	Eaton Laboratories, Inc.	Treating cardiac arrhythmias with dantrolene sodium
HU187215B (en) *	1983-01-26	1985-11-28	Egyt Gyogyszervegyeszeti Gyar	Method for producing pharmaceutical product of high actor content and prolonged effect
US4609675A (en) *	1984-08-17	1986-09-02	The Upjohn Company	Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4743612A (en) *	1986-10-17	1988-05-10	Berlex Laboratories, Inc.	Prodrug derivatives of the cardiotonic agent 4-ethyl-1,3-dihydro-5-(4-(2-methyl-1H-imidazol-1-yl)benzoyl)-2H-imidazol-2-one, composition containing them, and method of using them to treat cardiac failure
DE3705055A1 (de) *	1987-02-18	1988-09-01	Boehringer Ingelheim Kg	Verwendung von 2-(3-fluor-4-methylphenylimino)-imidazolidin zur behandlung der koronaren herzkrankheit
JP2518854B2 (ja) *	1987-06-19	1996-07-31	旭化成工業株式会社	固形製剤の製法
DE3739779A1 (de) *	1987-11-24	1989-06-08	Beiersdorf Ag	Pharmazeutische praeparate
SE506179C2 (sv) *	1989-01-23	1997-11-17	Ciba Geigy Ag	Farmaceutisk lågkomposition av benazepril och ett tiaziddiuretikum
GB8909793D0 (en)	1989-04-28	1989-06-14	Beecham Group Plc	Pharmaceutical formulation
DE122010000024I1 (de)	1990-02-19	2010-07-08	Novartis Ag	Acylverbindungen
AU8710691A (en) *	1990-09-28	1992-04-28	Mcneill-Ppc Inc.	Ibuprofen-diuretic combinations
EP0553777B1 (de) *	1992-01-29	2002-04-24	Takeda Chemical Industries, Ltd.	Schnellösliche Tablette und ihre Herstellung
IL104755A0 (en)	1992-02-17	1993-06-10	Ciba Geigy Ag	Treatment of glaucoma
US5395627A (en) *	1992-09-04	1995-03-07	Akzo N.V.	Pharmaceutical granulate
IT1255522B (it) *	1992-09-24	1995-11-09	Ubaldo Conte	Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
AU5449194A (en)	1992-10-26	1994-05-24	Merck & Co., Inc.	Combinations of angiotensin-ii receptor antagonists and diuretics
EP0676967A4 (de)	1992-12-30	1996-10-02	Fmc Corp	Leicht verfügbarer hilfsstoff zur verzögerten freisetzung auf der basis von konjac glukomannan.
JP3057471B2 (ja) *	1993-06-07	2000-06-26	武田薬品工業株式会社	アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
US5464854A (en)	1993-11-11	1995-11-07	Depadova; Anathony S.	Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S.
AT401871B (de) *	1994-01-28	1996-12-27	Gebro Broschek Gmbh	Verfahren zur herstellung von s(+)-ibuprofen- partikeln mit verbesserten fliesseigenschaften und deren verwendung zur arzneimittelherstellung
JP3534130B2 (ja) *	1994-03-01	2004-06-07	旭化成ケミカルズ株式会社	医薬品組成物
GB9404010D0 (en) *	1994-03-02	1994-04-20	Opt Tel Services Limited	Telephone dialling monitoring and route selecting apparatus
EP0750500A1 (de) *	1994-03-17	1997-01-02	Ciba-Geigy Ag	Behandlung von diabetischer nephropatie mit valsartan
GB9408117D0 (en)	1994-04-23	1994-06-15	Smithkline Beecham Corp	Pharmaceutical formulations
DE19502065C2 (de) *	1995-01-14	1996-05-02	Prophyta Biolog Pflanzenschutz	Pilzisolat mit fungizider Wirkung
US5994348A (en) *	1995-06-07	1999-11-30	Sanofi	Pharmaceutical compositions containing irbesartan
FR2735365B1 (fr) *	1995-06-14	1997-09-05	Sanofi Sa	Utilisation d'un antagoniste de l'angiotensine ii et d'un derive du benzofurane pour la preparation d'un medicament utile dans le traitement des affections cardiovasculaires
GB9613470D0 (en) *	1996-06-27	1996-08-28	Ciba Geigy Ag	Small solid oral dosage form
JP2011123241A (ja) *	2009-12-10	2011-06-23	Canon Inc	撮影システム

1996
- 1996-06-27 GB GBGB9613470.5A patent/GB9613470D0/en active Pending
1997
- 1997-06-14 MY MYPI97002679A patent/MY123149A/en unknown
- 1997-06-14 MY MYPI20041863A patent/MY146868A/en unknown
- 1997-06-14 MY MYPI20093392A patent/MY156312A/en unknown
- 1997-06-18 CN CNB971958912A patent/CN1133427C/zh not_active Expired - Lifetime
- 1997-06-18 AT AT03027840T patent/ATE371449T1/de active
- 1997-06-18 EP EP06126819A patent/EP1767206B1/de not_active Revoked
- 1997-06-18 DK DK06126819.9T patent/DK1767206T3/da active
- 1997-06-18 DK DK03027840T patent/DK1410797T3/da active
- 1997-06-18 CA CA2673462A patent/CA2673462C/en not_active Expired - Fee Related
- 1997-06-18 CA CA002259148A patent/CA2259148C/en not_active Expired - Fee Related
- 1997-06-18 AT AT06126819T patent/ATE446749T1/de active
- 1997-06-18 DE DE69738089T patent/DE69738089T2/de not_active Expired - Lifetime
- 1997-06-18 KR KR1020067011260A patent/KR20060079260A/ko not_active Ceased
- 1997-06-18 KR KR1020097017936A patent/KR101161283B1/ko not_active Expired - Fee Related
- 1997-06-18 CN CN2006100999105A patent/CN1951372B/zh not_active Expired - Lifetime
- 1997-06-18 BR BR9709956A patent/BR9709956A/pt not_active Application Discontinuation
- 1997-06-18 HU HU0203374A patent/HU229134B1/hu not_active IP Right Cessation
- 1997-06-18 US US09/202,805 patent/US6294197B1/en not_active Expired - Lifetime
- 1997-06-18 CZ CZ0426998A patent/CZ296850B6/cs not_active IP Right Cessation
- 1997-06-18 KR KR1020057015071A patent/KR100792389B1/ko not_active Expired - Fee Related
- 1997-06-18 RU RU99101056/63D patent/RU2294743C2/ru not_active IP Right Cessation
- 1997-06-18 PT PT03027840T patent/PT1410797E/pt unknown
- 1997-06-18 EP EP06126834A patent/EP1776953A1/de not_active Withdrawn
- 1997-06-18 SI SI9730773T patent/SI1410797T1/sl unknown
- 1997-06-18 ES ES06126819T patent/ES2335683T3/es not_active Expired - Lifetime
- 1997-06-18 KR KR1020117011286A patent/KR101208430B1/ko not_active Expired - Fee Related
- 1997-06-18 TR TR1998/02698T patent/TR199802698T2/xx unknown
- 1997-06-18 KR KR1020087000538A patent/KR20080014149A/ko not_active Ceased
- 1997-06-18 DE DE69739642T patent/DE69739642D1/de not_active Expired - Lifetime
- 1997-06-18 PL PL97330709A patent/PL188233B1/pl not_active IP Right Cessation
- 1997-06-18 EP EP06126838A patent/EP1767207A3/de not_active Withdrawn
- 1997-06-18 PT PT97929209T patent/PT914119E/pt unknown
- 1997-06-18 EP EP03027840A patent/EP1410797B1/de not_active Revoked
- 1997-06-18 DE DE69730834T patent/DE69730834T2/de not_active Expired - Lifetime
- 1997-06-18 PL PL97363524A patent/PL188271B1/pl unknown
- 1997-06-18 IL IL12756497A patent/IL127564A0/xx unknown
- 1997-06-18 PT PT06126819T patent/PT1767206E/pt unknown
- 1997-06-18 EP EP09001681A patent/EP2055301A1/de not_active Withdrawn
- 1997-06-18 EP EP97929209A patent/EP0914119B1/de not_active Expired - Lifetime
- 1997-06-18 WO PCT/EP1997/003172 patent/WO1997049394A2/en not_active Ceased
- 1997-06-18 ES ES97929209T patent/ES2231873T3/es not_active Expired - Lifetime
- 1997-06-18 CN CN031466788A patent/CN1475207B/zh not_active Expired - Lifetime
- 1997-06-18 NZ NZ333385A patent/NZ333385A/xx not_active IP Right Cessation
- 1997-06-18 EP EP06126829A patent/EP1774967A1/de not_active Withdrawn
- 1997-06-18 DK DK97929209T patent/DK0914119T3/da active
- 1997-06-18 JP JP10502269A patent/JP2000506540A/ja active Pending
- 1997-06-18 ES ES03027840T patent/ES2290400T3/es not_active Expired - Lifetime
- 1997-06-18 AT AT97929209T patent/ATE276750T1/de active
- 1997-06-18 RU RU99101056/14A patent/RU2203054C2/ru active IP Right Maintenance
- 1997-06-18 SK SK1784-98A patent/SK285902B6/sk not_active IP Right Cessation
- 1997-06-18 SI SI9730686T patent/SI0914119T1/xx unknown
- 1997-06-18 KR KR1019980710521A patent/KR100618038B1/ko not_active Expired - Fee Related
- 1997-06-23 CO CO97034775A patent/CO4870755A1/es unknown
- 1997-06-24 PE PE1997000539A patent/PE87498A1/es not_active IP Right Cessation
- 1997-06-25 AR ARP970102790A patent/AR008618A1/es active IP Right Grant
- 1997-06-26 ZA ZA9705673A patent/ZA975673B/xx unknown
- 1997-06-26 ID IDP972207A patent/ID17553A/id unknown
- 1997-09-09 TW TW086113018A patent/TW473394B/zh not_active IP Right Cessation
1998
- 1998-12-22 NO NO19986056A patent/NO317181B1/no not_active IP Right Cessation
2001
- 2001-08-01 US US09/920,159 patent/US6485745B1/en not_active Expired - Fee Related
2002
- 2002-09-20 US US10/251,009 patent/US6858228B2/en not_active Expired - Fee Related
2003
- 2003-01-23 JP JP2003014987A patent/JP2003231634A/ja not_active Withdrawn
- 2003-02-21 NZ NZ524346A patent/NZ524346A/en not_active IP Right Cessation
2004
- 2004-03-26 NO NO20041287A patent/NO331739B1/no not_active IP Right Cessation
2006
- 2006-03-21 CY CY0600007A patent/CY2553B1/xx unknown
2007
- 2007-01-10 RU RU2007100200/15A patent/RU2453306C2/ru not_active IP Right Cessation
- 2007-02-06 AR ARP070100474A patent/AR059324A2/es not_active Application Discontinuation
- 2007-06-28 JP JP2007170267A patent/JP4969338B2/ja not_active Expired - Lifetime
2008
- 2008-11-17 IL IL195339A patent/IL195339A0/en unknown
2009
- 2009-04-27 RU RU2009115778/15A patent/RU2009115778A/ru unknown
2011
- 2011-12-09 JP JP2011270429A patent/JP2012051948A/ja not_active Withdrawn
2013
- 2013-03-26 RU RU2013113610/15A patent/RU2013113610A/ru not_active Application Discontinuation
- 2013-10-25 JP JP2013221985A patent/JP2014012747A/ja active Pending

Also Published As

Publication number	Publication date
EP1776953A1 (de)	2007-04-25
HUP0203374A3 (en)	2004-06-28
EP1410797B1 (de)	2007-08-29
US6485745B1 (en)	2002-11-26
RU2007100200A (ru)	2008-07-20
HK1019858A1 (en)	2000-06-09
JP2012051948A (ja)	2012-03-15
AU724998B2 (en)	2000-10-05
CN1951372A (zh)	2007-04-25
JP4969338B2 (ja)	2012-07-04
JP2003231634A (ja)	2003-08-19
CA2673462A1 (en)	1997-12-31
SK285902B6 (sk)	2007-10-04
US6858228B2 (en)	2005-02-22
SI0914119T1 (en)	2005-04-30
PT914119E (pt)	2005-02-28
SK178498A3 (en)	1999-06-11
CY2553B1 (en)	2008-07-02
KR20060079260A (ko)	2006-07-05
ES2231873T3 (es)	2005-05-16
NO317181B1 (no)	2004-09-06
US20030035832A1 (en)	2003-02-20
DE69730834D1 (de)	2004-10-28
NZ524346A (en)	2004-09-24
RU2009115778A (ru)	2010-11-10
ZA975673B (en)	1997-12-29
DE69730834T2 (de)	2005-10-06
KR20080014149A (ko)	2008-02-13
SI1410797T1 (sl)	2008-08-31
JP2000506540A (ja)	2000-05-30
CN1475207A (zh)	2004-02-18
AR008618A1 (es)	2000-02-09
NZ333385A (en)	2000-09-29
NO20041287L (no)	2004-03-26
NO986056L (no)	1998-12-22
KR100618038B1 (ko)	2006-11-30
CO4870755A1 (es)	1999-12-27
TR199802698T2 (xx)	1999-04-21
MY123149A (en)	2006-05-31
AU3340297A (en)	1998-01-14
MY146868A (en)	2012-09-28
EP1767206B1 (de)	2009-10-28
ATE446749T1 (de)	2009-11-15
PL188271B1 (pl)	2005-01-31
EP1767206A2 (de)	2007-03-28
HU229134B1 (en)	2013-08-28
RU2203054C2 (ru)	2003-04-27
PT1410797E (pt)	2007-12-03
CN1133427C (zh)	2004-01-07
RU2013113610A (ru)	2014-10-10
ATE371449T1 (de)	2007-09-15
PL188233B1 (pl)	2004-12-31
JP2014012747A (ja)	2014-01-23
EP0914119A2 (de)	1999-05-12
TW473394B (en)	2002-01-21
PT1767206E (pt)	2010-01-27
DK0914119T3 (da)	2005-01-31
ID17553A (id)	1998-01-08
KR100792389B1 (ko)	2008-01-08
PL330709A1 (en)	1999-05-24
CA2259148A1 (en)	1997-12-31
IL195339A0 (en)	2009-08-03
WO1997049394A2 (en)	1997-12-31
ES2335683T3 (es)	2010-03-31
DK1767206T3 (da)	2010-01-25
RU2294743C2 (ru)	2007-03-10
KR20050092054A (ko)	2005-09-16
EP2055301A1 (de)	2009-05-06
BR9709956A (pt)	1999-08-10
CN1951372B (zh)	2011-03-23
KR101208430B1 (ko)	2012-12-05
CN1475207B (zh)	2010-09-29
HUP0203374A2 (hu)	2004-05-28
GB9613470D0 (en)	1996-08-28
CZ296850B6 (cs)	2006-07-12
DE69739642D1 (de)	2009-12-10
KR20000022111A (ko)	2000-04-25
AR059324A2 (es)	2008-03-26
EP0914119B1 (de)	2004-09-22
NO986056D0 (no)	1998-12-22
ES2290400T3 (es)	2008-02-16
EP1410797A1 (de)	2004-04-21
EP1767206A3 (de)	2007-04-18
CZ426998A3 (cs)	1999-03-17
WO1997049394A3 (en)	2001-12-20
MY156312A (en)	2016-01-29
EP1774967A1 (de)	2007-04-18
CA2259148C (en)	2009-09-29
KR20090099020A (ko)	2009-09-18
US6294197B1 (en)	2001-09-25
ATE276750T1 (de)	2004-10-15
DE69738089T2 (de)	2008-05-21
DK1410797T3 (da)	2007-10-15
CN1232394A (zh)	1999-10-20
KR20110063587A (ko)	2011-06-10
PE87498A1 (es)	1998-12-21
EP1767207A2 (de)	2007-03-28
KR101161283B1 (ko)	2012-07-02
JP2007238637A (ja)	2007-09-20
CA2673462C (en)	2011-10-04
DE69738089D1 (de)	2007-10-11
NO331739B1 (no)	2012-03-12
EP1767207A3 (de)	2007-04-18
RU2453306C2 (ru)	2012-06-20
EP0914119A3 (de)	2002-03-06
HK1060700A1 (en)	2004-08-20

Publication	Publication Date	Title
IL195339A0 (en)	2009-08-03	Solid oral dosage forms of valsartan
HUP9903407A3 (en)	2000-11-28	Oral pharmaceutical preparation containing ibandronat
HUP9901454A3 (en)	2001-04-28	Dosage form of ibuprofen
EP1020193A4 (de)	2006-05-24	Orale präparation
EG24077A (en)	2008-05-11	Oral 2-methyl-thieno-benzodiazepine formulation
ZA96365B (en)	1996-08-06	New oral pharmaceutical dosage form
HUP9802913A3 (en)	2000-06-28	Bioadhesive solid dosage form
IL110014A0 (en)	1994-10-07	Solid controlled-release oral dosage forms
PL341428A1 (en)	2001-04-09	Oral pharmacological dosage form of prolonged release type
HUP0003757A3 (en)	2001-07-30	Oral pharmaceutical compositions of levosimendan
IL138192A0 (en)	2001-11-25	Controlled release oral dosage forms
ZA976189B (en)	1999-01-11	Oral pharmaceutical combinations
HUP9904345A3 (en)	2000-11-28	Oral contraceptive
PL340456A1 (en)	2001-02-12	Novel oral dosage form of carvedilol
GB9600390D0 (en)	1996-03-13	Preparation of tablets
GB9618964D0 (en)	1996-10-23	Oral composition
GB9411594D0 (en)	1994-08-03	Demagnetisation of materials
AU724998C (en)	2013-05-23	Solid oral dosage forms of valsartan
ZA974125B (en)	1998-11-13	Oral pharmaceutical compositions
IL126588A (en)	2000-12-06	Oral dosage forms of azithromycin for improved food-compatibility
GB9617560D0 (en)	1996-10-02	Oral cleanser
GB9707576D0 (en)	1997-06-04	Enhancement of oral hygiene
GB9407647D0 (en)	1994-06-08	Oral medicament
ZA976144B (en)	1999-01-11	Oral pharmaceutical compositions
AUPN996996A0 (en)	1996-06-13	Treatment of oral conditions